Patents by Inventor Didier Rotticci

Didier Rotticci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8188101
    Abstract: Dihydropyridopyrimidine compounds of formula (Ia) and therapeutically acceptable salts thereof, wherein R1, R2 and Z are as defined in the specification; processes for making them and methods for using them in the treatment of A?-related pathologies.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: May 29, 2012
    Assignee: AstraZeneca AB
    Inventors: Rickard Forsblom, Kim Paulsen, Didier Rotticci, Ellen Santangelo, Magnus Waldman
  • Publication number: 20120122843
    Abstract: The present invention relates to novel compounds of formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compounds, processes for making said compounds, and their use as medicaments for treatment and/or prevention of A?-related diseases.
    Type: Application
    Filed: November 9, 2011
    Publication date: May 17, 2012
    Applicant: ASTRAZENECA AB
    Inventors: István MACSÁRI, Kim PAULSEN, Laszlo RAKOS, Britt-Marie SWAHN, Magnus WALDMAN, Didier ROTTICCI, Stefan VON BERG
  • Publication number: 20110319426
    Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
    Type: Application
    Filed: September 6, 2011
    Publication date: December 29, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Jörg HOLENZ, Sofia KARLSTRÖM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SÖDERMAN, Britt-Marie SWAHN, Stefan VON BERG
  • Patent number: 8030500
    Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: October 4, 2011
    Assignee: AstraZeneca AB
    Inventors: Jörg Holenz, Sofia Karlström, Karin Kolmodin, Johan Lindström, Laszlo Rakos, Didier Rotticci, Peter Söderman, Britt-Marie Swahn, Stefan Von Berg
  • Publication number: 20100324072
    Abstract: This invention relates to novel compounds having the structural formula I below: (I) and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: May 14, 2008
    Publication date: December 23, 2010
    Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LTD.
    Inventors: Gianni Chessari, Miles Stuart Congreve, Jorg Holenz, Christopher Murray, Sahil Patel, Laszlo Rakos, Didier Rotticci
  • Publication number: 20100292210
    Abstract: The present invention relates to novel compounds of formulae I and II and therapeutically acceptable salts thereof, their pharmaceutical compositions processes for making them and their use in therapeutic methods for treatment and/or prevention of various diseases. In particular, the invention relates to compounds which interfere with ?-secretase and/or its substrate and hence modulate the formation of A? peptides.
    Type: Application
    Filed: May 11, 2010
    Publication date: November 18, 2010
    Applicant: AstraZeneca AB
    Inventors: Yvonne Lo-Alfredsson, Kim Paulsen, Laszlo Rakos, Didier Rotticci, Magnus Waldman
  • Publication number: 20100130495
    Abstract: The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases.
    Type: Application
    Filed: November 6, 2009
    Publication date: May 27, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Rickard FORSBLOM, Kim PAULSEN, Didier ROTTICCI, Ellen SANTANGELO, Magnus WALDMAN
  • Publication number: 20100125082
    Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
    Type: Application
    Filed: November 13, 2009
    Publication date: May 20, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Jörg HOLENZ, Sofia KARLSTRÖM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SÖDERMAN, Britt-Marie SWAHN, Stefan VON BERG
  • Publication number: 20100125081
    Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
    Type: Application
    Filed: November 13, 2009
    Publication date: May 20, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Jorg HOLENZ, Sofia KARLSTROM, Jacob KIHLSTROM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SODERMAN, Marie SUNDSTROM, Britt-Marie SWAHN, Stefan VON BERG
  • Patent number: 7645784
    Abstract: Compounds of formula I, wherein R1, m, R2, R3, p, n, R5 and R9 are as defined as in the specification, salts, solvates or solvated salts thereof, processes for their preparation, intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and the use of said compounds in therapy.
    Type: Grant
    Filed: May 13, 2004
    Date of Patent: January 12, 2010
    Assignee: AstraZeneca AB
    Inventors: Yevgeni Besidski, Inger Kers, Martin Nylöf, Didier Rotticci, Andis Slaitas, Mats Svensson
  • Patent number: 7629356
    Abstract: This invention relates to substituted pyrrolo[3,4-b]pyridinamines having the structural formula IA below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: December 8, 2009
    Assignees: AstraZeneca AB, Astex Therapeutics
    Inventors: Gianni Chessari, Miles Stuart Congreve, Jörg Holenz, Christopher Murray, Sahil Patel, Laszlo Rakos, Didier Rotticci
  • Publication number: 20090270470
    Abstract: Compounds of formula I, wherein R1, Z, X, Y, M and R2 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical composition containing the same, methods of using the same for therapeutic purposes and methods of making the same.
    Type: Application
    Filed: May 8, 2006
    Publication date: October 29, 2009
    Applicant: AstraZeneca AB
    Inventors: Catrin Jonasson, Hakan Molin, Berit Molin, Didier Rotticci
  • Publication number: 20090233945
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: May 15, 2008
    Publication date: September 17, 2009
    Applicants: AstraZeneca AB, Astex Therapeutics Limited
    Inventors: Gianni Chessari, Miles Stuart Congreve, Jorg Holenz, Christopher Murray, Sahil Patel, Laszlo Rakos, Didier Rotticci
  • Publication number: 20090105252
    Abstract: Compounds of formula I wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification as a base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, processes for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: October 2, 2006
    Publication date: April 23, 2009
    Applicant: AstraZeneca AB
    Inventors: Lars Andersson, Erwan Arzel, Stefan Berg, Jeremy Burrows, Sven Hellberg, Fernando Huerta, Torben Pedersen, Tobias Rein, Didier Rotticci, Karin Staaf, Dominika Turek
  • Publication number: 20090054453
    Abstract: The present invention relates to new compounds of formula I, or salts, solvates or solvated salts thereof, wherein Q, R1, R2, R3, R4 and n are defined as in claim 1, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: March 15, 2007
    Publication date: February 26, 2009
    Inventors: Lilian Alcaraz, Gunnar Nordvall, Didier Rotticci, Daniel Sohn
  • Publication number: 20090030038
    Abstract: The present invention relates to new compounds of formula I. (I) wherein R1 to R12, X, Q and n are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: May 22, 2006
    Publication date: January 29, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Chester Chu, Andrew Lister, Gunnar Nordvall, Carl Petersson, Didier Rotticci, Daniel Sohn, Stefan Von Berg
  • Publication number: 20080287462
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: May 15, 2008
    Publication date: November 20, 2008
    Applicants: AstraZeneca AB, Astex Therapeutics Limited
    Inventors: Gianni Chessari, Miles Stuart Congreve, Jorg Holenz, Christopher Murray, Sahil Patel, Laszlo Rakos, Didier Rotticci
  • Publication number: 20080255106
    Abstract: Compounds of formula I wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, as a base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, processes for their preparation and new intermediates used therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: October 2, 2006
    Publication date: October 16, 2008
    Applicant: AstraZeneca AB
    Inventors: Per I. Arvidsson, Erwan Arzel, Jeremy Burrows, Helena Gyback, Tobias Rein, Didier Rotticci, Peter Soderman
  • Publication number: 20080255085
    Abstract: Compounds of formula I wherein X is or Y; and wherein A, Y, R1, R2, R3, R4 and R5 are as defined in the specification as a base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, processes for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: October 2, 2006
    Publication date: October 16, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Per I Arvidsson, Erwan Arzel, Jeremy Burrows, Martina Claesson, Colin Ray, Tobias Rein, Didier Rotticci, Peter Soderman
  • Publication number: 20080214577
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: June 11, 2007
    Publication date: September 4, 2008
    Applicants: AstraZeneca AB, Astex Therapeutics Ltd
    Inventors: Stefan Berg, Jorg Holenz, Katharina Hogdin, Karin Kolmodin, Niklas Plobeck, Didier Rotticci, Fernando Sehgelmeble, Maria Wirstam